Cervical (GYN)

Adrenal Gland/Adrenocortical Basket Trials (Multiple Types) Biliary Tract/Gall Bladder/Cholangiocarcinoma (GI) Bladder/Urothelial (GU) Bone Metastases Brain and Central Nervous System (CNS) Breast Cervical (GYN) Colon/Rectal/Anal (GI) Endocrine Cancers Endocrine Neoplasia Esophageal (GI) Gastric/Stomach (GI) Gastrointestinal (GI) (Multiple Types) General Solid Tumors (Multiple Types) GenitoUrinary (GU) (Multiple Types) GEP-NET (NEC) GI Stromal Tumor (GIST) Gynecologic (GYN) (Multiple Types) Head and Neck Cancers Hepatocellular/Liver (GI) Hodgkins Lymphoma Insulinoma Kidney/Renal Cell Carcinoma (GU) Leukemias Lung Lymphomas Melanoma/Skin Cancers Mesothelioma Multiple Myeloma NeuroBlastoma NeuroEndocrine (NEC) (Multiple Types) NeuroEndocrine Carcinoma (NEC) Osteosarcoma Ovarian Ovarian/Primary Peritoneal (GYN) Pancreatic (GI) Paraganglioma (NEC) Penile (GU) Pheochromocytoma (NEC) Prostate (GU) Salivary Gland Sarcoma Synovial Carcinoma Testicular (GU) Thymoma Thyroid Unknown Primary Cancers Uterine (GYN) Vulvar (GYN)

Last Updated: Wed Jul 17 2024

Study Status

Enrolling

On Hold

Not Enrolling

Unknown

🇦🇺

🇨🇦

🇺🇸

Treatment Metastatic Cancer

Ac225 FPI-1434 in Breast, Cervical, Uterine, Ovarian, Melanoma, & Head/Neck Cancers

NCT04459273

PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

NCT04008095

Evaluation of the Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer at an Advanced Stage. Multicenter Prospective Observational Study

A lot of studies have demonstrated the prognostic value of post therapy 18F-FDG PET/CT in the management of uterine cervical cancer. Post therapy 18F-FDG PET/CT is usually requested by a lot of clinicians. Whereas 18F-FDG PET/CT is useful for prognosis in the follow-up, data are yet insufficient to clearly establish a formal recommendation. This prospective multicenter observational study will evaluate the interest of post therapy 18F-FDG PET/CT in clinical management (within 2 months of treatment) in patients with cervical cancer at an advanced stage.

NCT05283330

A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors

NCT04514692

Phase 1 2 Study of Individualized Bone Marrow Sparing Image Guided Radiotherapy Incorporating Novel Use of Granulocyte Colony Stimulating Factor and FDG PET Imaging

This is a research study using Granulocyte Colony Stimulating Factor (GCSF) as a bone marrow stimulating agent for imaging to guide radiation treatment planning. G-CSF is a type of growth factor. Growth factors are proteins made in the body. G-CSF is a type of growth factor that makes the bone marrow produce white blood cells to reduce the risk of infection after some types of cancer treatment.